Rectal Adenocarcinoma Clinical Trial
— AuditCROfficial title:
Audit of the Quality of Surgical Treatment of Colorectal Cancer
NCT number | NCT04349384 |
Other study ID # | SCOD 2 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2018 |
Est. completion date | December 31, 2019 |
Verified date | April 2020 |
Source | Institut National d'Oncologie, Morocco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of this project is to audit the surgical care in patients treated for colorectal adenocarcinoma. This study focused on collecting data from all consecutive cases of colon and rectal adenocarcinoma operated at the National Institute of Oncology in Rabat during a two-years period. Using standardized forms, the investigators collected data relating to each stage of treatment: pre-therapeutic, surgical and post-operative in order to measure the quality of the surgical care delivered. These results were compared to established benchmarks and to similar audit studies carried out in other countries around the world.
Status | Completed |
Enrollment | 136 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with histologically proven colorectal adenocarcinoma who underwent surgical resection with curative intent between 1 January 2018 and 31 December 2019. Exclusion Criteria: - Colon or rectal resections for other histologic types than adenocarcinoma. - Palliative intent surgery. |
Country | Name | City | State |
---|---|---|---|
Morocco | Institut National d'Oncologie | Rabat |
Lead Sponsor | Collaborator |
---|---|
Institut National d'Oncologie, Morocco |
Morocco,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Retrieved lymph nodes | Number patients with retrieved lymph nodes after colon resection above 12 | 1 month after surgery | |
Primary | Positive circumferential margin | The rate of patients with circumferential margin < 1 mm on surgical specimen of rectal resection for rectal adenocarcinoma. | 1 month after surgery | |
Primary | Morbidity | Morbidity assessed using using the Clavien-Dindo grading system at discharge and at 90 days after surgical resection for colorectal adenocarcinoma | 90 days after surgery | |
Secondary | Pre-operative CT-scan | Rate of patients who had computed tomography before surgery | 7 days after surgery | |
Secondary | Multidisciplinary team meeting | Rate of cases who were discussed during a multidisciplinary team meeting before surgery for patients who had surgical resection for colorectal adenocarcinoma | 7 days after surgery | |
Secondary | MRI for rectal adenocarcinoma | Rate pf patients who had a pelvic Magnetic resonance imaging or rectal ultra-sonography in the pre-operative work-up of rectal adenocarcinoma | 7 days after surgery | |
Secondary | Anastomotic leakage | Rate of anastomotic leakage after resection of colorectal cancer with the creation of anastomosis | 90 days after surgery | |
Secondary | Readmission | Rate of hospital readmissions leakage after resection of colorectal cancer | 90 days after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05081024 -
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
|
||
Not yet recruiting |
NCT04090450 -
Optimisation of Radiotherapy in Rectal Cancer (ORREC)
|
||
Recruiting |
NCT06050447 -
Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
|
||
Terminated |
NCT02233595 -
Evaluation of Rectal Cancer Treatment Response Using PET/MRI
|
||
Completed |
NCT02935309 -
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
|
Phase 1 | |
Terminated |
NCT01887509 -
Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology
|
N/A | |
Recruiting |
NCT05746195 -
Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)
|
N/A | |
Active, not recruiting |
NCT03365882 -
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT02314182 -
GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis
|
Phase 3 | |
Completed |
NCT02393755 -
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04441580 -
Assessing the Additional Neoplasia Yield of Computer-aided Colonoscopy in a Screening Setting
|
N/A | |
Terminated |
NCT03527784 -
Prestoma-Trial for Parastomal Hernia Prevention
|
N/A | |
Completed |
NCT00855946 -
Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy
|
N/A | |
Recruiting |
NCT06328361 -
Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer
|
N/A | |
Recruiting |
NCT02107105 -
Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
|
||
Terminated |
NCT03300544 -
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03436563 -
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04814784 -
Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum
|
||
Recruiting |
NCT05482516 -
Evaluating Novel Therapies in ctDNA Positive GI Cancers
|
Phase 3 | |
Completed |
NCT02368886 -
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 2 |